Google Translate Disclaimer

A number of pages on the Government of Saskatchewan's website have been professionally translated in French. These translations are identified by a yellow box in the right or left rail that resembles the link below. The home page for French-language content on this site can be found at:

Renseignements en Français

Where an official translation is not available, Google™ Translate can be used. Google™ Translate is a free online language translation service that can translate text and web pages into different languages. Translations are made available to increase access to Government of Saskatchewan content for populations whose first language is not English.

Software-based translations do not approach the fluency of a native speaker or possess the skill of a professional translator. The translation should not be considered exact, and may include incorrect or offensive language. The Government of Saskatchewan does not warrant the accuracy, reliability or timeliness of any information translated by this system. Some files or items cannot be translated, including graphs, photos and other file formats such as portable document formats (PDFs).

Any person or entities that rely on information obtained from the system does so at his or her own risk. Government of Saskatchewan is not responsible for any damage or issues that may possibly result from using translated website content. If you have any questions about Google™ Translate, please visit: Google™ Translate FAQs.

Summary of COVID-19 vaccine AEFI reports received in Saskatchewan

As of September 10, 2023, a cumulative total of 1,377 reportable AEFI reports have been received, following 2,857,445 doses of COVID-19 vaccines administered in Saskatchewan with a reporting rate of 0.48 per 1,000 doses administered (0.048% of all doses administered). Refer to Tables 1 and 2 for more details.

Table 1: Summary of COVID-19 Vaccine AEFI Reports Received in Saskatchewan, as of September 10, 2023

  Pfizer
BA.1
Bivalent
Pfizer 12+
BA.4/5
Bivalent
Pfizer
5-11
BA.4/5
Bivalent
Pfizer
12+
Pfizer
5-11
Pfizer
6 mo-4yr
Moderna
18+ BA.1
Bivalent
Moderna
BA.4/5
Bivalent
Moderna
6+
Moderna
6 mo-5yr
Astra
Zeneca 18+
COVI-
SHIELD
18+
Janssen
18+
Novavax 12+ Totals
Total number of doses administered 45 137,207 1,964 1,843,023 124,483 7,012 98,660 8,453 528,946 12,843 75,145 17,124 2,017 523 2,857,445
Total number of AEFI reports received 0 18 0 856 15 5 7 0 327 6 113 25 4 1 1,377
Number of non-serious reports 0 17 0 791 14 5 6 0 313 6 95 24 3 1 1,275
Number of serious reports1 0 1 0 65 1 0 1 0 14 0 18 1 1 0 102
Proportion of serious AEFI reports 0% 5.6% 0% 7.6% 6.7% 0% 14.3% 0% 4.3% 0% 15.9% 4% 25% 0% 7.4%
Total AEFI reporting rate per 1,000 doses administered 0 0.13 0 0.46 0.12 0.71 0.07 0 0.62 0.47 1.51 1.46 1.98 1.91 0.48
Serious AEFI reporting rate per 1,000 doses administered 0 0.01 0 0.04 0.01 0 0.01 0 0.03 0 0.24 0.06 0.5 0 0.04

1Serious criteria includes an adverse event that is life threatening or results in death, requires hospitalization or prolongation of an existing hospitalization, results in residual disability or causes congenital malformation.

Table 2: Cumulative Frequency of AEFIs Reported

Adverse event type # of events
Edema (allergic, not injection site) 309
Rashes (all) 264
Anesthesia/paresthesia 225
Injection site reactions 200
Gastrointestinal 151
Anaphylaxis 83
Chest tightness 70
Headache 68
Arthralgia/arthritis/joint pain 50
Malaise/lethargy 46
Fever 40
Not inclusive of all AEFIs that can be reported

There are safety signals identified by the Public Health Agency of Canada (PHAC) for vaccine-induced immune thrombotic thrombocytopenia (VITT)/thrombosis with thrombocytopenia syndrome (TTS), myocarditis/pericarditis, Guillain-Barre Syndrome (GBS) and capillary leak syndrome (CLS) requiring provinces and territories to report these events as adverse events of special interest to the PHAC. As of September 10, 2023, 3 TTS, 36 myocarditis/pericarditis, 2 GBS and 0 CLS cases have been reported in Saskatchewan.

Information on reported adverse events following COVID-19 vaccination in Canada can be found at the PHAC AEFI reporting site at COVID-19 vaccine safety: Weekly report on side effects following immunization on Canada.ca.

We need your feedback to improve saskatchewan.ca. Help us improve